{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T16:42:05Z","timestamp":1777653725178,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Polish MNiSW","award":["N N401 647340"],"award-info":[{"award-number":["N N401 647340"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.bbr.2013.12.019","type":"journal-article","created":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T19:16:20Z","timestamp":1387307780000},"page":"79-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Chronic l-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra"],"prefix":"10.1016","volume":"261","author":[{"given":"Jolanta","family":"Konieczny","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Czarnecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Lenda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga","family":"Kami\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u017cbieta","family":"Lorenc-Koci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2013.12.019_bib0005","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1007\/BF01485901","article-title":"Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system","volume":"38","author":"Ehringer","year":"1960","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.bbr.2013.12.019_bib0010","series-title":"Handbuch der Neurologie","first-page":"920","article-title":"Paralysis agitans. I. Pathologische anatomic","author":"Lewy","year":"1912"},{"key":"10.1016\/j.bbr.2013.12.019_bib0015","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","article-title":"\u03b1-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies","volume":"95","author":"Spillantini","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl.17","key":"10.1016\/j.bbr.2013.12.019_bib0020","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1002\/mds.21675","article-title":"The pathogenesis of cell death in Parkinson's disease \u2013 2007","volume":"22","author":"Olanow","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2013.12.019_bib0025","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0896-6273(03)00606-8","article-title":"The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg","volume":"40","author":"Ciechanover","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.bbr.2013.12.019_bib0030","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/35086067","article-title":"Failure of the ubiquitin-proteasome system in Parkinson's disease","volume":"2","author":"McNaught","year":"2001","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.bbr.2013.12.019_bib0035","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/33416","article-title":"Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism","volume":"392","author":"Kitada","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.bbr.2013.12.019_bib0040","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/26652","article-title":"The ubiquitin pathway in Parkinson's disease","volume":"395","author":"Leroy","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.bbr.2013.12.019_bib0045","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the \u03b1-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.bbr.2013.12.019_bib0050","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0304-3940(00)01701-8","article-title":"Proteasomal function is impaired in substantia nigra in Parkinson's disease","volume":"297","author":"McNaught","year":"2001","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bbr.2013.12.019_bib0055","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1006\/exnr.2002.8050","article-title":"Altered proteasomal function in sporadic Parkinson's disease","volume":"179","author":"McNaught","year":"2003","journal-title":"Exp Neurol"},{"key":"10.1016\/j.bbr.2013.12.019_bib0060","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1523\/JNEUROSCI.23-26-08955.2003","article-title":"Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition","volume":"23","author":"Fornai","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.bbr.2013.12.019_bib0065","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1096\/fj.07-8386com","article-title":"Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators","volume":"21","author":"Zhu","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.bbr.2013.12.019_bib0070","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12640-012-9374-z","article-title":"The extent of neurodegeneration and neuroprotection in two chemical in vitro models related to Parkinson's disease is critically dependent on cell culture conditions","volume":"24","author":"Jantas","year":"2013","journal-title":"Neurotox Res"},{"key":"10.1016\/j.bbr.2013.12.019_bib0075","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1471-4159.2002.00821.x","article-title":"Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures","volume":"81","author":"McNaught","year":"2002","journal-title":"J Neurochem"},{"key":"10.1016\/j.bbr.2013.12.019_bib0080","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.expneurol.2006.07.010","article-title":"Comparison of the neurotoxic effects of proteasomal inhibitors in primary mesencephalic cultures","volume":"202","author":"Reaney","year":"2006","journal-title":"Exp Neurol"},{"key":"10.1016\/j.bbr.2013.12.019_bib0085","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1046\/j.1471-4159.2001.00474.x","article-title":"Proteasomal inhibition leads to formation of ubiquitin\/alpha-synuclein-immunoreactive inclusions in PC12 cells","volume":"78","author":"Rideout","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.bbr.2013.12.019_bib0090","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.neuint.2011.03.013","article-title":"Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats","volume":"58","author":"Lorenc-Koci","year":"2011","journal-title":"Neurochem Int"},{"key":"10.1016\/j.bbr.2013.12.019_bib0095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.expneurol.2013.03.021","article-title":"Direct intranigral administration of an ubiquitin proteasome system inhibitor in rat: behavior, positron emission tomography, immunohistochemistry","volume":"247","author":"Mackey","year":"2013","journal-title":"Exp Neurol"},{"key":"10.1016\/j.bbr.2013.12.019_bib0100","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1097\/00001756-200208070-00018","article-title":"Proteasome inhibition causes nigral degeneration with inclusion bodies in rats","volume":"13","author":"McNaught","year":"2002","journal-title":"Neuroreport"},{"key":"10.1016\/j.bbr.2013.12.019_bib0105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000202972","article-title":"Nigral degeneration with inclusion body formation and behavioral changes in rats after proteasomal inhibition","volume":"87","author":"Niu","year":"2009","journal-title":"Stereotact Funct Neurosurg"},{"key":"10.1016\/j.bbr.2013.12.019_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2202-11-1","article-title":"Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease","volume":"11","author":"Vernon","year":"2010","journal-title":"BMC Neurosci"},{"key":"10.1016\/j.bbr.2013.12.019_bib0115","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.neulet.2005.01.024","article-title":"Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition","volume":"380","author":"Miwa","year":"2005","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bbr.2013.12.019_bib0120","doi-asserted-by":"crossref","first-page":"e17269","DOI":"10.1371\/journal.pone.0017269","article-title":"Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's disease","volume":"6","author":"Vernon","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bbr.2013.12.019_bib0125","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0166-4328(89)80121-4","article-title":"Selective lesion of central dopamine or noradrenaline neuron systems in the neonatal rat: motor behavior and monoamine alterations at adult stage","volume":"33","author":"Luthman","year":"1989","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bbr.2013.12.019_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-2952(75)90304-4","article-title":"Mechanisms of action of 6-hydroxydopamine","volume":"24","author":"Sachs","year":"1975","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bbr.2013.12.019_bib0135","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1023\/A:1015160323009","article-title":"6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease","volume":"21","author":"Elkon","year":"2001","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.bbr.2013.12.019_bib0140","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1385\/JMN:24:3:387","article-title":"Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease","volume":"24","author":"Elkon","year":"2004","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.bbr.2013.12.019_bib0145","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1046\/j.1471-4159.2003.01952.x","article-title":"Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease","volume":"86","author":"H\u00f6glinger","year":"2003","journal-title":"J Neurochem"},{"key":"10.1016\/j.bbr.2013.12.019_bib0150","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0006-8993(91)91399-L","article-title":"Chronic l-DOPA treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance","volume":"568","author":"Carey","year":"1991","journal-title":"Brain Res"},{"key":"10.1016\/j.bbr.2013.12.019_bib0155","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/exnr.1998.6819","article-title":"Characterization of enhanced behavioral responses to l-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease","volume":"151","author":"Henry","year":"1998","journal-title":"Exp Neurol"},{"key":"10.1016\/j.bbr.2013.12.019_bib0160","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0306-4522(02)00013-1","article-title":"Drug-induced rotation intensity in unilateral dopamine-depleted rats is not correlated with end point or qualitative measures of forelimb or hindlimb motor performance","volume":"111","author":"Metz","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2013.12.019_bib0165","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.bbr.2006.03.021","article-title":"Expression of dyskinetic movements and turning behaviour in subchronic l-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment","volume":"171","author":"Pinna","year":"2006","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bbr.2013.12.019_bib0170","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1523\/JNEUROSCI.09-09-03326.1989","article-title":"Evidence that l-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms","volume":"9","author":"Robertson","year":"1989","journal-title":"J Neurosci"},{"key":"10.1016\/j.bbr.2013.12.019_bib0175","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0301-0082(96)00040-8","article-title":"The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments","volume":"50","author":"Schwarting","year":"1996","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.bbr.2013.12.019_bib0180","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.brainres.2006.09.027","article-title":"Subchronic administration of l-DOPA to adult rats with a unilateral 6-hydroxydopamine lesion of dopamine neurons results in a sensitization of enhanced GABA release in the substantia nigra, pars reticulata","volume":"1123","author":"Yamamoto","year":"2006","journal-title":"Brain Res"},{"key":"10.1016\/j.bbr.2013.12.019_bib0185","series-title":"The rat brain in stereotaxic coordinates","author":"Paxinos","year":"1986"},{"key":"10.1016\/j.bbr.2013.12.019_bib0190","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00002826-198403000-00005","article-title":"l-DOPA methyl ester: a candidate for chronic systemic delivery of l-DOPA in Parkinson's disease","volume":"7","author":"Cooper","year":"1984","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.bbr.2013.12.019_bib0195","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1734-1140(11)70541-2","article-title":"Time course of changes in rotational behavior and DA metabolism in rats lesioned unilaterally with selective proteasome inhibitor lactacystin","volume":"63","author":"Konieczny","year":"2011","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.bbr.2013.12.019_bib0200","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.neuropharm.2005.04.002","article-title":"MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats","volume":"49","author":"Ossowska","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2013.12.019_bib0205","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S1734-1140(10)70264-4","article-title":"Buspirone improves 6-hydroxydopamine-induced catalepsy through stimulation of nigral 5-HT(1A) receptors in rats","volume":"62","author":"Nayebi","year":"2010","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.bbr.2013.12.019_bib0210","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0028-3908(00)00005-8","article-title":"CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury","volume":"39","author":"Schallert","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2013.12.019_bib0215","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-201X.1971.tb11000.x","article-title":"Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system","volume":"367","author":"Ungerstedt","year":"1971","journal-title":"Acta Physiol Scand (Suppl)"},{"key":"10.1016\/j.bbr.2013.12.019_bib0220","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.neuint.2013.09.021","article-title":"Molsidomine, a nitric oxide donor, modulates rotational behavior and monoamine metabolism in 6-OHDA lesioned rats treated chronically with l-DOPA","volume":"63","author":"Lorenc-Koci","year":"2013","journal-title":"Neurochem Int"},{"key":"10.1016\/j.bbr.2013.12.019_bib0225","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","article-title":"Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease","volume":"164","author":"Duty","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bbr.2013.12.019_bib0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2011.03.031","article-title":"Time-course gait analysis of hemiparkinsonian rats following 6-hydroxydopamine lesion","volume":"222","author":"Hsieh","year":"2011","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bbr.2013.12.019_bib0235","series-title":"Central nervous system disease: innovative models of CNS diseases from molecule to therapy","first-page":"131","article-title":"Intervention strategies for degeneration of dopamine neurons in parkinsonism: optimizing behavioral assessment of outcome","author":"Schallert","year":"1999"},{"key":"10.1016\/j.bbr.2013.12.019_bib0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2005.02.023","article-title":"Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice","volume":"162","author":"Iancu","year":"2005","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bbr.2013.12.019_bib0245","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0014-2999(89)90790-5","article-title":"Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists","volume":"168","author":"Engber","year":"1989","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2013.12.019_bib0250","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bbr.2008.01.012","article-title":"Hemiparkinsonian rats rotate toward the side with the weaker dopaminergic neurotransmission","volume":"189","author":"Da Cunha","year":"2008","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bbr.2013.12.019_bib0255","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0006-8993(93)90576-9","article-title":"Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats","volume":"626","author":"Hudson","year":"1993","journal-title":"Brain Res"},{"key":"10.1016\/j.bbr.2013.12.019_bib0260","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1046\/j.1432-1033.2002.02808.x","article-title":"Ubiquitination of soluble and membrane-bound tyrosine hydroxylase and degradation of the soluble form","volume":"269","author":"D\u00f8skeland","year":"2002","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.bbr.2013.12.019_bib0265","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/B978-0-12-411512-5.00001-4","article-title":"Intracellular stability of tyrosine hydroxylase: phosphorylation and proteasomal digestion of the enzyme","volume":"68","author":"Nakashima","year":"2013","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.bbr.2013.12.019_bib0270","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0304-3940(88)90382-5","article-title":"Evidence that the substantia nigra is a site of action for l-DOPA","volume":"89","author":"Robertson","year":"1988","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bbr.2013.12.019_bib0275","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/0014-4886(92)90203-3","article-title":"Simultaneous microdialysis in striatum and substantia nigra suggests that the nigra is a major site of action of l-dihydroxyphenylalanine in the \u201chemiparkinsonian\u201d rat","volume":"115","author":"Orosz","year":"1992","journal-title":"Exp Neurol"},{"key":"10.1016\/j.bbr.2013.12.019_bib0280","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00498985","article-title":"Substantia nigra as an out-put station for striatal dopaminergic responses: role of a GABA-mediated inhibition of pars reticulata neurons","volume":"306","author":"Di Chiara","year":"1979","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.bbr.2013.12.019_bib0285","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF00236638","article-title":"Lesions of the globus pallidus, entopeduncular nucleus and substantia nigra alter dopamine mediated circling behaviour","volume":"52","author":"Dewar","year":"1983","journal-title":"Exp Brain Res"},{"key":"10.1016\/j.bbr.2013.12.019_bib0290","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1016\/S0021-9258(19)42751-8","article-title":"The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents","volume":"249","author":"Cohen","year":"1974","journal-title":"J Biol Chem"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432813007626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432813007626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T23:52:12Z","timestamp":1647733932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432813007626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":58,"alternative-id":["S0166432813007626"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2013.12.019","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic l-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2013.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}